Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Apr 27, 2018 2:20pm
101 Views
Post# 27951475

RE:RE:New Institutional holders & Egrifta sales

RE:RE:New Institutional holders & Egrifta salesAbit more digging.

You can access their historical holdings also and they dont show holding any in Dec 2017. It also shows they paid an average price of 7.24. So they must have accumulated in Jan/Feb after the extension was announced and in the run up to approval. Nice timing!

(btw SPCEO I dont see where you got 1.3million shares.Bloomberg.ca shows 670,000 and that is the only holding in any of their mutual fund. Maybe they hold some in other investment vehicles, idk, but I'd check your number)

PoorOpinion wrote: FWIW, a bit of detective work.

All Artisans shares are being held in their Artisan International Small Cap Fund

https://www.artisanpartners.com/content/dam/documents/holdings/vfund/2018/1q/InternationalSmCap-Holdings-1Q18-vFund.pdf

That fund strategy

https://www.artisanpartners.com/content/dam/documents/investment-process/vr/Investment-Process-Global-Equity-Team-vR.pdf

from their buy/sell strategy

"Stock markets move share prices around far more than the change in the underlying fundamental value of a company. This creates opportunities for us to buy good companies when the market has lost faith in them "


you can see why they picked theratech :)






SPCEO1 wrote: On Bloomberg, Artisan Partners now shows up as holding almost 1.3 million shares and is the third largest shareholder listed (Ibelieve there are other shareholders who hold positions larger than even oours but they don't file their holdings because they don't have to). Royal Bank, through the O'Shaughnessy Funds, is the fourth largest holder listed on Bloomberg with 780,000 shares. Blackrock also has established a small holding. So, while someone is clearly keeping a lid on the stock with their selling recently, there have been some institutiions getting involved. There are surely more who would want to own the stock but since none of the large holders are interested in selling, they can't get big positions without pushing the share price up and they are not willing to do that yet.   
Meanwhile,we have seen a pick-up in Egrifta sales in recent weeks based on the Bloomberg data. Nothing huge but there has likely been a positive impact now that the salespeople are getting into see the doctors to tell them about Trogarzo.Every little bit helps! 




Bullboard Posts